Astellas Submits Application For Vesicare Oral Disintegration Tablets
This article was originally published in PharmAsia News
Executive Summary
To maximum product value, Astellas Dec. 22 submitted an approval application for overactive bladder drug Vesicare (solifenacin) oral disintegration tablets in Japan
You may also be interested in...
Biden Regulatory Freeze May Pause Sunset Rule, Medicare Rebate, Medicaid Line Extension Regs
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
US FDA Still “Actively” Drafting Proposed Licensing Rule For Wholesalers and 3PLs
Pharmaceutical manufacturers should have already begun serializing products and verifying saleable returns to comply with DSCSA, says FDA official who also asserted that licensing standards for wholesale distributors and third-party logistics providers will be forthcoming. This rule is already six years overdue under a DSCSA mandated timeline.
P&G Boosts Guidance Again Despite Dipping 'Consumption Levels' Expected Through June
On a “strong first half of the base,” P&G increased FY2021 guidance for organic sales growth and core earnings per share despite a “sequential deceleration” in US consumption in its categories in December and so far in January.
Need a specific report? 1000+ reports available
Buy Reports